Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 3

Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy

Authors Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG

Published Date October 2011 Volume 2011:3 Pages 59—68

DOI http://dx.doi.org/10.2147/DHPS.S15599

Published 7 October 2011

Ayman M Noreddin1, Walid F Elkhatib2, Kenji M Cunnion3, George G Zhanel4
1Department of Pharmacy Practice, Hampton University, Hampton, VA, USA; 2Department of Microbiology and Immunology, Ain-Shams University, Cairo, Egypt; 3Department of Pediatrics, East Virginia Medical School, Norfolk, VA, USA; 4Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada

Abstract: Levofloxacin is the synthetic L-isomer of the racemic fluoroquinolone, ofloxacin. It interferes with critical processes in the bacterial cell such as DNA replication, transcription, repair, and recombination by inhibiting bacterial topoisomerases. Levofloxacin has broad spectrum activity against several causative bacterial pathogens of community-acquired pneumonia (CAP). Oral levofloxacin is rapidly absorbed and is bioequivalent to the intravenous formulation such that patients can be conveniently transitioned between these formulations when moving from the inpatient to the outpatient setting. Furthermore, levofloxacin demonstrates excellent safety, and has good tissue penetration maintaining adequate concentrations at the site of infection. The efficacy and tolerability of levofloxacin 500 mg once daily for 10 days in patients with CAP are well established. Furthermore, a high-dose (750 mg) and short-course (5 days) of once-daily levofloxacin has been approved for use in the US in the treatment of CAP, acute bacterial sinusitis, acute pyelonephritis, and complicated urinary tract infections. The high-dose, short-course levofloxacin regimen maximizes its concentration-dependent antibacterial activity, decreases the potential for drug resistance, and has better patient compliance.

Keywords: levofloxacin, community-acquired pneumonia, pharmacodynamics, resistance, pharmacokinetics, clinical use

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Role of endothelin receptor A and NADPH oxidase in vascular abnormalities

De-Zai Dai, Yin Dai

Vascular Health and Risk Management 2010, 6:787-794

Published Date: 3 September 2010

New stent design for use in small coronary arteries during percutaneous coronary intervention

Juan F Granada, Barbara A Huibregtse, Keith D Dawkins

Medical Devices: Evidence and Research 2010, 3:57-66

Published Date: 19 October 2010

Liraglutide in the management of type 2 diabetes

Estela Wajcberg, Amatur Amarah

Drug Design, Development and Therapy 2010, 4:279-290

Published Date: 22 October 2010

Amino acid management of Parkinson’s disease: a case study

Marty Hinz, Alvin Stein, Thomas Uncini

International Journal of General Medicine 2011, 4:165-174

Published Date: 28 February 2011

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011